134 related articles for article (PubMed ID: 25683232)
1. Simultaneous plasma and genital pharmacokinetics and pharmacodynamics of atazanavir and efavirenz in HIV-infected women starting therapy.
Neely M; Louie S; Xu J; Anthony P; Thuvamontolrat K; Mordwinkin N; Kovacs A
J Clin Pharmacol; 2015 Jul; 55(7):798-808. PubMed ID: 25683232
[TBL] [Abstract][Full Text] [Related]
2. Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen.
Meditz AL; Palmer C; Predhomme J; Searls K; Kerr B; Seifert S; Caraway P; Gardner EM; MaWhinney S; Anderson PL
AIDS Res Hum Retroviruses; 2015 Oct; 31(10):1015-22. PubMed ID: 26059647
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study.
Scarsi KK; Cramer YS; Rosenkranz SL; Aweeka F; Berzins B; Coombs RW; Coughlin K; Moran LE; Zorrilla CD; Akelo V; Aziz M; Friedman RK; Gingrich D; Swaminathan S; Godfrey C; Cohn SE;
Lancet HIV; 2019 Sep; 6(9):e601-e612. PubMed ID: 31498109
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
[TBL] [Abstract][Full Text] [Related]
5. Minimum effective plasma concentration of efavirenz in treatment-naïve Chinese HIV-infected patients.
Sun J; Chen J; Yao Y; Zhang R; Zheng Y; Liu L; Zhang L; Shen Y; Lu H
Int J STD AIDS; 2010 Dec; 21(12):810-3. PubMed ID: 21297088
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study.
Xu L; Peng W; Song X; Li Y; Han Y; Zhu T; Fu Q; Du X; Cao W; Li T
BMC Infect Dis; 2021 Jan; 21(1):112. PubMed ID: 33485301
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).
Castillo-Mancilla JR; Aquilante CL; Wempe MF; Smeaton LM; Firnhaber C; LaRosa AM; Kumarasamy N; Andrade A; Baheti G; Fletcher CV; Campbell TB; Haas DW; MaWhinney S; Anderson PL
J Antimicrob Chemother; 2016 Jun; 71(6):1609-18. PubMed ID: 26892777
[TBL] [Abstract][Full Text] [Related]
8. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study.
Puls RL; Srasuebkul P; Petoumenos K; Boesecke C; Duncombe C; Belloso WH; Molina JM; Li L; Avihingsanon A; Gazzard B; Cooper DA; Emery S;
Clin Infect Dis; 2010 Oct; 51(7):855-64. PubMed ID: 20735258
[TBL] [Abstract][Full Text] [Related]
9. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
[TBL] [Abstract][Full Text] [Related]
10. Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals.
Cain LE; Caniglia EC; Phillips A; Olson A; Muga R; Pérez-Hoyos S; Abgrall S; Costagliola D; Rubio R; Jarrín I; Bucher H; Fehr J; van Sighem A; Reiss P; Dabis F; Vandenhende MA; Logan R; Robins J; Sterne JAC; Justice A; Tate J; Touloumi G; Paparizos V; Esteve A; Casabona J; Seng R; Meyer L; Jose S; Sabin C; Hernán MA;
Medicine (Baltimore); 2016 Oct; 95(41):e5133. PubMed ID: 27741139
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting.
Marinaro L; Calcagno A; Ripamonti D; Cenderello G; Pirriatore V; Trentini L; Salassa B; Bramato C; Orofino G; D'Avolio A; Rizzi M; Di Perri G; Rusconi S; Bonora S
J Clin Virol; 2017 Feb; 87():30-36. PubMed ID: 27992788
[TBL] [Abstract][Full Text] [Related]
12. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
Podany AT; Bao Y; Swindells S; Chaisson RE; Andersen JW; Mwelase T; Supparatpinyo K; Mohapi L; Gupta A; Benson CA; Kim P; Fletcher CV;
Clin Infect Dis; 2015 Oct; 61(8):1322-7. PubMed ID: 26082504
[TBL] [Abstract][Full Text] [Related]
13. Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort.
Postorino MC; Prosperi M; Quiros-Roldan E; Maggiolo F; Di Giambenedetto S; Saracino A; Costarelli S; Lorenzotti S; Sighinolfi L; Di Pietro M; Torti C;
Clin Microbiol Infect; 2015 Apr; 21(4):386.e1-9. PubMed ID: 25595708
[TBL] [Abstract][Full Text] [Related]
14. Response to efavirenz plus two nucleoside reverse-transcriptase inhibitors in patients with advanced stage human immunodeficiency virus-1 infection in Taiwan.
Deng SC; Chen MY; Hsieh SM; Sheng WH; Hsiao CF; Hung CC; Chang SC
J Microbiol Immunol Infect; 2003 Mar; 36(1):10-4. PubMed ID: 12741726
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and correlates of persistent intracellular HIV transcription in individuals on efavirenz versus atazanavir-based regimens: A prospective cohort study.
Pilalas D; Skoura L; Margariti A; Chatzopoulou F; Chatzidimitriou D; Tsachouridou O; Zebekakis P; Metallidis S; Papaioannou M
PLoS One; 2018; 13(3):e0194262. PubMed ID: 29534103
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml.
Imaz A; Llibre JM; Navarro J; Curto J; Clotet B; Crespo M; Ferrer E; Saumoy M; Tiraboschi JM; Murillo O; Podzamczer D
Antivir Ther; 2014; 19(6):569-77. PubMed ID: 24458091
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
; Carey D; Puls R; Amin J; Losso M; Phanupak P; Foulkes S; Mohapi L; Crabtree-Ramirez B; Jessen H; Kumar S; Winston A; Lee MP; Belloso W; Cooper DA; Emery S
Lancet Infect Dis; 2015 Jul; 15(7):793-802. PubMed ID: 25877963
[TBL] [Abstract][Full Text] [Related]
18. Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial).
Gallien S; Journot V; Rozenbaum W; Yéni P; Morlat P; Poizot-Martin I; Reynes J; Reliquet V; Leclercq P; Simon F; Chêne G; Molina JM;
J Antimicrob Chemother; 2011 Jan; 66(1):184-91. PubMed ID: 21036772
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
Dumond JB; Yeh RF; Patterson KB; Corbett AH; Jung BH; Rezk NL; Bridges AS; Stewart PW; Cohen MS; Kashuba AD
AIDS; 2007 Sep; 21(14):1899-907. PubMed ID: 17721097
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
Rockstroh JK; Lennox JL; Dejesus E; Saag MS; Lazzarin A; Wan H; Walker ML; Xu X; Zhao J; Teppler H; Dinubile MJ; Rodgers AJ; Nguyen BY; Leavitt R; Sklar P;
Clin Infect Dis; 2011 Oct; 53(8):807-16. PubMed ID: 21921224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
